Bruce L. Levine

8 ta ish

University of Pennsylvania

1. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

   Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

   Maqola20187 iqtibos

   ABIABI:AkademIndex/2026.other.312621

2. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

   Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.020482

3. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

   Stephan A. Grupp, Michael Kalos, David M. Barrett +10

   MaqolaOAOchiq kirish20133 iqtibos

   ABIABI:AkademIndex/2026.other.082765

4. CRISPR-engineered T cells in patients with refractory cancer

   Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

   MaqolaOAOchiq kirish20203 iqtibos

   ABIABI:AkademIndex/2026.other.102870

5. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

   Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando +34

   MaqolaOAOchiq kirish20182 iqtibos

   ABIABI:AkademIndex/2026.other.020493

6. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

   Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.082777

7. Global Manufacturing of CAR T Cell Therapy

   Bruce L. Levine, James Miskin, Keith Wonnacott +1

   Sharh maqola20172 iqtibos

   ABIABI:AkademIndex/2026.other.296823

8. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

   Joseph A. Fraietta, Christopher L. Nobles, Morgan A. Sammons +35

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.475807